top of page
Search

Rapid Review: Tumor Markers List (MRCP Part 1)

TL;DR: 

Tumour markers are a high-yield topic in MRCP Part 1, typically tested through clinical associations and interpretation rather than recall alone. This Rapid Review: Tumor Markers List focuses on the most examinable markers, their key associations, and common pitfalls. Prioritise understanding when markers are useful (monitoring) and when they mislead (false positives).


Why this matters

Tumour markers frequently appear in MRCP Part 1 questions because they integrate oncology with general medicine, hepatology, and endocrinology. The exam rarely tests obscure markers—instead, it focuses on classic associations, interpretation in clinical context, and limitations.

Candidates often lose marks by:

  • Treating tumour markers as diagnostic tests

  • Ignoring benign causes of elevation

  • Missing pattern-based questions

A structured approach will improve both accuracy and speed. Start with the core list, then build clinical reasoning through practice on platforms like the MRCP Part 1 overview and apply concepts using Free MRCP MCQs.


Core high-yield tumour markers

Must-know exam table

Tumour Marker

Associated Malignancy

Key Exam Notes

AFP (Alpha-fetoprotein)

Hepatocellular carcinoma, non-seminomatous germ cell tumours

Also ↑ in cirrhosis (trap)

β-hCG

Germ cell tumours, choriocarcinoma

Also ↑ in pregnancy

PSA

Prostate cancer

Raised in BPH, prostatitis

CEA

Colorectal cancer

Monitoring, not screening

CA-125

Ovarian cancer

Elevated in endometriosis

CA 19-9

Pancreatic cancer

Poor specificity

Calcitonin

Medullary thyroid cancer

MEN2 association

Thyroglobulin

Differentiated thyroid cancer

Follow-up marker

LDH

Lymphoma, germ cell tumours

Tumour burden marker

ALP

Bone metastases, liver disease

Non-specific


The 5 most tested subtopics

1. AFP and liver pathology

AFP is strongly associated with hepatocellular carcinoma (HCC), particularly in patients with chronic liver disease. However, it can also be elevated in cirrhosis and hepatitis, making it a classic MRCP trap.

👉 Exam tip: A rising AFP with a liver lesion is more important than a single value.

2. Germ cell tumour markers

  • AFP + β-hCG ↑ → non-seminomatous tumours

  • β-hCG alone ↑ → seminoma (occasionally)

  • LDH correlates with tumour burden

👉 Expect questions linking markers to testicular masses in young males.

3. PSA interpretation

PSA is commonly tested for its limitations:

  • Elevated in prostate cancer

  • Also elevated in benign prostatic hyperplasia (BPH) and prostatitis

👉 MRCP focus: PSA is not a perfect screening tool.

4. CA-125 pitfalls

CA-125 is associated with ovarian cancer but rises in:

  • Endometriosis

  • Pelvic inflammatory disease

  • Pregnancy

👉 High-yield concept: Low specificity = exam trap

5. Calcitonin and MEN syndromes

Calcitonin is a key marker for medullary thyroid carcinoma and is strongly linked to MEN2 syndrome.

👉 Often tested in genetic or endocrine questions.


Rapid recall: 10 exam facts

  1. Tumour markers are not diagnostic alone

  2. Most useful for monitoring recurrence or treatment response

  3. AFP → HCC + germ cell tumours

  4. CEA is not used for screening

  5. PSA lacks specificity

  6. CA-125 has many benign causes

  7. Calcitonin → medullary thyroid carcinoma

  8. LDH reflects tumour burden

  9. β-hCG is elevated in pregnancy

  10. Always interpret markers in clinical context

Medical student revising tumour markers for MRCP Part 1 exam with notes and flashcards

Practical example (MCQ)

A 62-year-old man with a history of alcohol-related cirrhosis presents with weight loss and right upper quadrant pain. Blood tests show a markedly elevated AFP. Imaging reveals a solitary liver lesion.

What is the most likely diagnosis? A. Metastatic colorectal cancerB. Hepatocellular carcinomaC. CholangiocarcinomaD. Liver abscess

Answer: B. Hepatocellular carcinoma

Explanation: AFP is strongly associated with HCC, particularly in patients with cirrhosis. While mild elevations can occur in chronic liver disease, a marked rise with a focal lesion strongly suggests malignancy.


Common pitfalls (exam traps)

  • ❌ Assuming tumour markers confirm diagnosis

  • ❌ Ignoring benign causes (e.g., CA-125 in endometriosis)

  • ❌ Using PSA or CEA as screening tools without context

  • ❌ Forgetting physiological causes (pregnancy → β-hCG)

  • ❌ Relying on a single value instead of trends


Practical study checklist

  • ✅ Memorise 10 core tumour markers only

  • ✅ Learn associations, not lists

  • ✅ Focus on false positives (high-yield traps)

  • ✅ Practise clinical vignettes regularly

  • ✅ Use timed revision via Start a mock test

  • ✅ Integrate tumour markers with system-based revision (GI, endocrine, oncology)

For structured revision, combine this with a broader oncology review and question practice through the Crack Medicine platform.


FAQs

1. Are tumour markers used for screening in MRCP Part 1?

Rarely. Most tumour markers lack sufficient sensitivity and specificity for screening and are primarily used for monitoring treatment response or recurrence.

2. Which tumour markers are most important for MRCP Part 1?

Focus on AFP, PSA, CEA, CA-125, β-hCG, and calcitonin. These account for the majority of exam questions.

3. Can tumour markers be elevated in benign conditions?

Yes. Many tumour markers have non-malignant causes, which are commonly tested to assess clinical reasoning.

4. How should I revise tumour markers efficiently?

Use pattern recognition + MCQs. Avoid rote memorisation—focus on associations and interpretation in clinical scenarios.

5. Is LDH a tumour marker?

Yes, but it is non-specific. It reflects tumour burden and is commonly elevated in lymphoma and germ cell tumours.


Ready to start?

Tumour markers are best mastered through pattern recognition and question-based learning. Consolidate your understanding with targeted practice on the Free MRCP MCQs and build exam confidence using the MRCP Part 1 overview.


Sources

 
 
 

Comments

bottom of page